The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2020

Filed:

Mar. 22, 2019
Applicant:

Fred Hutchinson Cancer Research Center, Seattle, WA (US);

Inventors:

Marie Bleakley, Seattle, WA (US);

Robson Dossa, Shoreline, WA (US);

Daniel Sommermeyer, Munich, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); A61P 35/02 (2018.01); C07K 14/70517 (2013.01); C12N 5/0636 (2013.01); C07K 2319/41 (2013.01);
Abstract

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).


Find Patent Forward Citations

Loading…